Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31 with the first subjects now dosed in this ...

In the past year, shares of Merck have plunged 21.7% compared with the industry’s decrease of 2.6%. Image Source ... to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults aged 18 ...

2 controlled studies in South Africa evaluated ... meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92%, respectively ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerabi ...